4,339 reports of this reaction
3.8% of all DEXLANSOPRAZOLE reports
#5 most reported adverse reaction
RENAL INJURY is the #5 most commonly reported adverse reaction for DEXLANSOPRAZOLE, manufactured by Takeda Pharmaceuticals America, Inc.. There are 4,339 FDA adverse event reports linking DEXLANSOPRAZOLE to RENAL INJURY. This represents approximately 3.8% of all 112,812 adverse event reports for this drug.
Patients taking DEXLANSOPRAZOLE who experience renal injury should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RENAL INJURY is moderately reported among DEXLANSOPRAZOLE users, representing a notable but not dominant share of adverse events.
In addition to renal injury, the following adverse reactions have been reported for DEXLANSOPRAZOLE:
The following drugs have also been linked to renal injury in FDA adverse event reports:
RENAL INJURY has been reported as an adverse event in 4,339 FDA reports for DEXLANSOPRAZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RENAL INJURY accounts for approximately 3.8% of all adverse event reports for DEXLANSOPRAZOLE, making it a notable side effect.
If you experience renal injury while taking DEXLANSOPRAZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.